GlassScriptPhysician profile
Najam Syed
NPI 1588688717
$7,157.09
in general payments reported to CMS, 2019-2025
40 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $758 · 2021: $1,343 · 2022: $1,069 · 2023: $1,113 · 2024: $929 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,388.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,373.02 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,109.24 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $768.32 | 2019-2025 | |
| Novo Nordisk INC | $576.20 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $564.68 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $307.13 | 2021-2025 | Caplyta |
| Allergan, INC. | $268.08 | 2019-2020 | |
| Exact Sciences Corporation | $249.34 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $244.14 | 2019-2025 | Zepbound, Kisunla, Jardiance |
| Amgen INC. | $170.20 | 2019-2024 | Repatha, Otezla |
| Ucb, INC. | $146.49 | 2020-2025 | Nayzilam |
| Novartis Pharmaceuticals Corporation | $138.06 | 2019-2024 | |
| Eisai INC. | $137.60 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $136.62 | 2022-2023 | Verquvo |
| Amarin Pharma, INC. | $99.80 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Najam Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.